RATIONALE: The interoceptive and reinforcing effects of 3,4-methylenedioxymethamphetamine (MDMA) are similar to those of psychostimulants, but the role of dopamine in the behavioral effects of MDMA is not well documented, especially in primates. OBJECTIVE: The aim of this study was to assess the role of dopamine in the behavioral effects of MDMA in two nonhuman primate species. METHODS: The behavioral effects of MDMA, with and without serotonergic or dopaminergic pretreatments, were studied in squirrel monkeys trained to respond under a fixed-interval schedule of stimulus termination; effects on caudate dopamine levels were studied in a separate group of squirrel monkeys using in vivo microdialysis. Positron emission tomography neuroimaging with the dopamine transporter (DAT) ligand [18F]FECNT was used to determine DAT occupancy by MDMA in rhesus monkeys. RESULTS: MDMA (0.5-1.5 mg/kg) did not induce behavioral stimulant effects, but the highest dose of MDMA suppressed responding. Pretreatment with fluoxetine (3.0 mg/kg) or the selective 5HT(2A) antagonist M100907 (0.03-0.3 mg/kg) attenuated the rate suppressing effects of MDMA. In contrast, pretreatment with the selective dopamine transporter inhibitor RTI-177 (0.1 mg/kg) did not alter the rate suppressing effects of MDMA. Administration of MDMA at a dose that suppressed operant behavior had negligible effects on extracellular dopamine. The percent DAT occupancy of MDMA at a dose that suppressed operant behavior also was marginal and reflected low in vivo potency for DAT binding. CONCLUSIONS: Collectively, these results indicate that behaviorally relevant doses of MDMA do not induce behavioral stimulant or dopamine transporter-mediated effects in nonhuman primates.
RATIONALE: The interoceptive and reinforcing effects of 3,4-methylenedioxymethamphetamine (MDMA) are similar to those of psychostimulants, but the role of dopamine in the behavioral effects of MDMA is not well documented, especially in primates. OBJECTIVE: The aim of this study was to assess the role of dopamine in the behavioral effects of MDMA in two nonhuman primate species. METHODS: The behavioral effects of MDMA, with and without serotonergic or dopaminergic pretreatments, were studied in squirrel monkeys trained to respond under a fixed-interval schedule of stimulus termination; effects on caudate dopamine levels were studied in a separate group of squirrel monkeys using in vivo microdialysis. Positron emission tomography neuroimaging with the dopamine transporter (DAT) ligand [18F]FECNT was used to determine DAT occupancy by MDMA in rhesus monkeys. RESULTS:MDMA (0.5-1.5 mg/kg) did not induce behavioral stimulant effects, but the highest dose of MDMA suppressed responding. Pretreatment with fluoxetine (3.0 mg/kg) or the selective 5HT(2A) antagonist M100907 (0.03-0.3 mg/kg) attenuated the rate suppressing effects of MDMA. In contrast, pretreatment with the selective dopamine transporter inhibitor RTI-177 (0.1 mg/kg) did not alter the rate suppressing effects of MDMA. Administration of MDMA at a dose that suppressed operant behavior had negligible effects on extracellular dopamine. The percent DAT occupancy of MDMA at a dose that suppressed operant behavior also was marginal and reflected low in vivo potency for DAT binding. CONCLUSIONS: Collectively, these results indicate that behaviorally relevant doses of MDMA do not induce behavioral stimulant or dopamine transporter-mediated effects in nonhuman primates.
Authors: W Slikker; R R Holson; S F Ali; M G Kolta; M G Paule; A C Scallet; D E McMillan; J R Bailey; J S Hong; F M Scalzo Journal: Neurotoxicology Date: 1989 Impact factor: 4.294
Authors: Michael A Taffe; Christopher C Lay; Stefani N Von Huben; Sophia A Davis; Rebecca D Crean; Simon N Katner Journal: Drug Alcohol Depend Date: 2005-11-11 Impact factor: 4.492
Authors: Vincent Setola; Sandra J Hufeisen; K Jane Grande-Allen; Ivan Vesely; Richard A Glennon; Bruce Blough; Richard B Rothman; Bryan L Roth Journal: Mol Pharmacol Date: 2003-06 Impact factor: 4.436
Authors: Elizabeth G Pitts; Adelaide R Minerva; Erika B Chandler; Jordan N Kohn; Meghan T Logun; Agnieszka Sulima; Kenner C Rice; Leonard L Howell Journal: Neuropsychopharmacology Date: 2017-04-20 Impact factor: 7.853
Authors: N W Gilpin; M J Wright; G Dickinson; S A Vandewater; J U Price; M A Taffe Journal: Pharmacol Biochem Behav Date: 2011-05-13 Impact factor: 3.533
Authors: Debra A Cooper; Heather L Kimmel; Daniel F Manvich; Karl T Schmidt; David Weinshenker; Leonard L Howell Journal: J Pharmacol Exp Ther Date: 2014-05-09 Impact factor: 4.030
Authors: Laís F Berro; Hannah Shields; Melis Odabas-Geldiay; Barbara O Rothbaum; Monica L Andersen; Leonard L Howell Journal: Exp Clin Psychopharmacol Date: 2018-06-25 Impact factor: 3.157
Authors: Kevin S Murnane; Jake Winschel; Karl T Schmidt; LaShaya M Stewart; Samuel J Rose; Kejun Cheng; Kenner C Rice; Leonard L Howell Journal: J Neurosci Date: 2013-08-14 Impact factor: 6.167